EMVision Medical Devices Limited announced additional encouraging findings from its pilot clinical trial. The single-site study, at the Princess Alexandra Hospital (PAH) in Brisbane, of patients with diagnosed ischaemic or haemorrhagic stroke, has been the first clinical study for EMVision's novel imaging technology. The primary endpoint was the collection of a dataset of stroke patients which improves the understanding of stroke on electromagnetic scattering effects in the brain. This end point was met, producing datasets that have enabled EMVision to advance its electromagnetic (EM) imaging algorithm development and observe the correlation of EMVision scans with "ground truth" CT and/or MRI scans. The contract research organisation (CRO) is Mobius Medical Pty Ltd. No intervention or modification to the standard of care of hospital-based treatment of stroke was done as part of this study. The Clinical Trial Summary is part of this announcement as Appendix A. The study was designed to collect data to tune the EMVision algorithms. The deidentified patient ground truth CT/MRI "training sets" made it possible for the algorithm team to refine the imaging and classification algorithms. Due to the design and sample size of the study, the dataset does not enable statistically significant conclusions to be drawn on diagnostic sensitivity/specificity. As previously advised, analysis performed on an initial 30 patient cohort was reported in October 2020. This analysis included classification observations of between 93% to 96% and localization observations of between 86% to 96% respectively. In addition, a fusion process was employed which involves leveraging data points from multiple algorithms to arrive at a final output. Please see ASX Release "EMVision reports very encouraging pilot clinical trial data" for further information. In total the study has enrolled and processed data from 50 patients (37 ischaemic and 13 haemorrhagic). The refined classification and localisation algorithms have been applied to the entire 50 patient dataset. The patients enrolled represent a diversity of stroke in localisation, size and clinical severity. The mean age was 67.7 years of age with the majority, 72% of patients, aged 60 years and over. There were equal numbers of male and female patients. Of the 50 patients, 29, (58%) had only a CT performed whereas 21, (42%) had CT/MRI performed. As a result of these scans, 26% of patients were diagnosed as having had a haemorrhagic stroke and 74% as having had an ischaemic stroke. National Institutes of Health Stroke Scale (NIHSS) was recorded for 49 patients. The NIHSS score is used to measure stroke severity. The mean NIHSS score was calculated as 5.9 which indicates mild-moderate severity. The participating patients' de- identified CT and/or MRI ground truth scans were interpreted and classified independently by EMVision clinical and radiology advisors. The EMVision device scans were acquired close to the timing of the corresponding ground truth scans. After the EMVision datasets were processed by the algorithm team, the classification algorithms and localisation algorithms outputs were verified by clinical advisors.